NEWS

NEWS

Total 11

11
News Update NeoImmuneTech and NIAID Embark on a Collaborative Study to Explore New Treatment for Acute Radiation Syndrome (ARS)
2023-06-20
10
News Update First Patient Dosed in Phase II Study of NeoImmuneTech’s NT-I7 plus Pembrolizumab in Recurrent Glioblastoma
2023-02-07
9
News Update Pharmaphorum highlights NeoImmuneTech
2022-12-19
8
News Update NeoImmuneTech to Present at 2023 Biotech Showcase
2022-12-15
7
News Update NeoImmuneTech Joins the United Nations Global Compact
2022-10-11
6
News Update NeoImmuneTech to Present at Cytokine-Based Drug Development Summit
2022-07-26
5
News Update Interest of Combining NeoImmuneTech’s Lead Asset NT-I7 (efineptakin alfa) with Pembrolizumab keeps Growing
2022-07-04
4
News Update NeoImmuneTech to Display its Environmental, Social, and Governance Activities on its Corporate Website
2022-06-30
3
News Update NeoImmuneTech to Present at Immuno-Oncology Summit Europe 2022
2022-05-19
2
News Update NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase II Study of NT-I7 and Pembrolizumab in Recurrent Glioblastoma
2022-05-11

1 2